Table 4.
Narratives of the 14 patients with a DoCE.
| DoCE no. | Time to DoCE (days) | DoCE presentation | Presumed cause of DoCE | Indication for index PCI | Targeted vessels | Lesion with complex features | Target vessel | No. of BRS in target lesion | BRS diameter (mm) | BRS length (mm) | P2Y12 inhibitor |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 4 | STEMI | Early ScT, presumably undersized scaffold | NSTEMI (UA) | 1 | BL (0,1,1) | Mid LAD | 2 | 3.0 | 25 | Clopidogrel |
| 2 | 20 | STEMI | Early ScT, premature discontinuation of DAPT* | CCS (angina) | 1 | BL (1,0,0) | Distal RCA | 1 | 3.0 | 25 | Ticagrelor |
| 3 | 29 | STEMI | Early ScT due to device collapse | CCS (staged PCI)† | 1 | No | Mid LAD | 1 | 3.5 | 25 | Ticagrelor |
| 4 | 42 | Elective PCI‡ | Device dismantling and collapse with RST | NSTEMI | 1 | BL (1,0,1) | Proximal LAD | 1 | 3.5 | 25 | Ticagrelor |
| 5 | 113 | Stable angina | Device dismantling and collapse with RST | CCS (angina; Instent-Restenosis) | 1 | ISR/ BL (0,0,1) | Proximal LAD | 1 | 3.0 | 20 | Clopidogrel |
| 6 | 142 | NSTEMI | Device dismantling and collapse with RST | CCS (angina) | No | Proximal LAD | 2 | 3.5 / 3.0 | 20 / 25 | Clopidogrel | |
| 7 | 373 | UA | Restenosis after scaffold dissolution | NSTEMI | 1 | No | Proximal LCx | 1 | 3.0 | 20 | Ticagrelor |
| 8 | 381 | STEMI | Very late ScT | NSTEMI | 1 | BL (1,0,0) | Proximal LAD | 2 | 3.5 | 25 / 20 | Ticagrelor |
| 9 | 427 | Stable angina | RST | CCS (angina) | 1 | ISR | Mid RCA | 2 | 3.25 | 25 | Clopidogrel |
| 10 | 453 | CV death | - | NSTEMI | - | No | - | - | - | - | - |
| 11 | 513 | UA | Device collapse and floating struts | NSTEMI (UA) | 1 | No | Proximal LAD | 1 | 3.5 | 25 | Prasugrel |
| 12 | 525 | NSTEMI | RST | NSTEMI | 1 | No | Mid RCA | 2 | 3.5 | 20 | Clopidogrel |
| 13 | 672 | STEMI | RST | CCS (angina) | 1 | No | Proximal to mid RCA | 3 | 3.0/3.5/3.5 | 25/25/15 | Ticagrelor |
| 14 | 1,835 | Stable angina | RST | CCS (angina) | 1 | No | Distal LAD | 1 | 2.5 | 25 | Clopidogrel |
BL, bifurcation lesion; BRS, bioresorbable scaffold; CCS, Chronic coronary syndrome; CV-death, cardiovascular death; DAPT, Dual antiplatelet therapy; DoCE, device-oriented composite endpoint; NSTEMI, Non-ST-segment elevation myocardial infarction; LAD, Left anterior descending coronary artery; LCX, Left circumflex coronary artery; PCI, Percutaneous coronary intervention; RCA, Right coronary artery; RST, Re-stenosis; ScT, Scaffold thrombosis; STEMI, ST-segment myocardial infarction; UA, Unstable angina.
Ticagrelor was paused prior to minimal invasive CABG surgery.
This patient had a staged PCI of a significant proximal LAD lesion after an inferior STEMI requiring RCA PCI.
Patient underwent elective PCI of the left circumflex. While doing so, Mg-BVS dismantling and collapse resulting in re-stenosis within the LAD was found (on OCT).